骨质疏松症 中国就医指南

Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to low-trauma fractures—most commonly at the spine, hip, and distal radius. It is a hallmark condition in endocrinology due to its strong association with hormonal imbalances, particularly estrogen deficiency in postmenopausal women and testosterone decline in aging men, as well as disorders of calcium, vitamin D, parathyroid hormone (PTH), and cortisol metabolism. Pathogenically, osteoporosis arises from an imbalance between bone resorption (mediated by overactive osteoclasts) and bone formation (impaired osteoblast function). Chronic inflammation, oxidative stress, mitochondrial dysfunction in bone cells, and dysregulated RANK/RANKL/OPG signaling further accelerate bone loss. Secondary causes—including glucocorticoid therapy, hyperthyroidism, primary hyperparathyroidism, type 1 diabetes, chronic kidney disease, and malabsorptive gastrointestinal disorders—account for up to 30% of cases and must be systematically evaluated in endocrine workup. Epidemiologically, osteoporosis affects over 90 million people in China alone, with prevalence rising sharply after age 50: approximately 32% of women and 6% of men aged ≥65 meet diagnostic criteria (based on WHO BMD T-score ≤−2.5). Globally, one in three women and one in five men over 50 will experience an osteoporotic fracture in their lifetime. Key modifiable risk factors include prolonged glucocorticoid use (>3 months, ≥5 mg prednisone/day), smoking, excessive alcohol intake (>3 drinks/day), sedentary lifestyle, low calcium/vitamin D intake, and chronic protein-energy malnutrition. Non-modifiable risks include advanced age, female sex, early menopause (<45 years), family history of hip fracture, and certain genetic variants (e.g., LRP5, SOST). Importantly, osteoporosis is often asymptomatic until a fragility fracture occurs—making it a 'silent epidemic.' Vertebral compression fractures may cause height loss, kyphosis, or chronic back pain; hip fractures carry high morbidity (20–25% 1-year mortality) and functional decline. Beyond physical disability, patients frequently report anxiety about falling, social withdrawal, depression, sleep disturbances, and diminished independence—significantly impairing health-related quality of life (HRQoL), as measured by tools like EQ-5D and SF-36. Early diagnosis via dual-energy X-ray absorptiometry (DXA), combined with FRAX® fracture risk assessment, enables timely intervention. Endocrinologists play a central role in identifying secondary causes, optimizing hormonal and metabolic parameters, and personalizing pharmacotherapy—including bisphosphonates, denosumab, teriparatide, romosozumab, and selective estrogen receptor modulators—alongside nutritional counseling, fall prevention, and supervised exercise.

# 骨质疏松症（内分泌科）治疗方案与费用明细

一、非手术/保守治疗

适用人群：骨量减少（T值 −1.0～−2.5）、轻中度骨质疏松（T值 ≤−2.5，无脆性骨折）、绝经后女性及老年男性初诊患者。

• •基础干预：钙剂（600–1200 mg/日）+维生素D₃（800–2000 IU/日）→ 年费用 300–800元
• •一线药物：阿仑膦酸钠（口服）→ 年药费 1200–2400元；唑来膦酸（静脉，每年1次）→ 单次 2800–4200元（含输注护理）
• •检查费：双能X线骨密度（DXA）检测（腰椎+股骨颈）280–360元；血清骨转换标志物（β-CTX、P1NP）320–450元/项

二、手术/微创介入治疗

适用人群：已发生椎体压缩性骨折（≥1节，疼痛持续>6周，保守无效）；需快速止痛与稳定脊柱者。

• •经皮椎体成形术（PVP）/椎体后凸成形术（PKP）：单节段 2.8–4.5万元；双节段 4.2–6.6万元（含术前MRI/CT 600–1200元、麻醉、材料、住院5–7天）

三、特殊复杂方案

适用人群：糖皮质激素诱导型、继发于甲旁亢/多发性骨髓瘤、严重骨微结构破坏（T值≤−3.5）或多次骨折者。

• •地诺单抗（60 mg皮下注射，每6个月1次）→ 单次 5800–6500元；特立帕肽（20 μg/d皮下，≤24个月）→ 年费用 9.6–11.2万元

四、方案快速选择指南

• •预算有限（<3000元/年）：钙+VD₃+阿仑膦酸钠+定期DXA监测
• •中高预算（1–5万元/年）：唑来膦酸或地诺单抗+骨代谢评估
• •急性骨折/功能受限：优先PKP/PVP联合抗骨质疏松药物序贯治疗